Background: Growing bacterial resistance remains a critical global health threat, underscoring the need for precision antibiotic delivery. Our research addresses this by developing CFT@MNZ-HDTMA for ceftriaxone (CFT) antibiotic. By utilizing a natural zeolite framework, this system optimizes the delivery and release kinetics of CFT, aiming to maximize clinical outcomes while minimizing adverse effects. Aim: The primary aim is to characterize the physicochemical properties of the CFT@MNZ-HDTMA system and elucidate its CFT release mechanisms through kinetic analysis. The study utilizes XRD and FTIR spectroscopy to determine the composite’s structural and chemical integrity. Furthermore, it evaluates the rate and consistency of drug release to establish a predictable kinetic model and explain the interaction between the antibiotic and the modified zeolite matrix. Materials and Methods: CFT delivery system was developed through the systematic modification of MNZ, with its structural and chemical properties characterized using XRD and FT-IR spectroscopy. The in vitro release kinetics of CFT from the carrier matrix were evaluated at 37°C over a 24-hour period, with drug concentrations quantified via UV-Vis spectrophotometry. Result: CFT was successfully adsorbed onto the surface of the MNZ-HDTMA. The subsequent release profiles demonstrated that CFT discharge remained constant over time and exhibited concentration-independent behavior, characteristic of zero-order kinetics. This mechanism ensured a controlled and sustained release of the therapeutic agent, facilitating a prolonged delivery window suitable for enhancing clinical efficacy. Conclusion Natural zeolite from the Tushleg deposit was processed through systematic modification to develop the CFT@MNZ-HDTMA drug delivery system. XRD and FT-IR analyses confirmed that the zeolite’s crystalline structure remained stable, while successfully demonstrating that the CFT was adsorbed onto the surface of the adsorbent through ionic interactions. Kinetic studies revealed that CFT is released from the system following a zero-order model (R2=0.9804), indicating a constant release rate. This proves the system’s practical significance in sustaining therapeutic effects and minimizing potential side effects.

World population relatively common viral diseasespread among the population are one of the mosttroubling health problems. Viral diseases includingherpes virus infections, herpes infections occurin many forms, including clinical herpes simplexinfections in the world are one of the common diseasesspread. HSV-1 and HSV-2 are transmitted by contactwith an infected area of the skin during reactivationsof the virus. Herpes simplex virus (HSV)-2 isperiodically shed in the human genital tract, most oftenasymptomatically, and most sexual transmissionsoccur during asymptomatic shedding. There have been many diagnostic techniques for HSV infections, including new viral detection methods and serological tests. We detection of herpes simlex virus by ELISA. Of 341 patient involved 43% (148) male, 57% (193) female. For all served patient 65.6% (224) were dominated by 20-40 years old. There were symptoms are herpes simplex virus infection in 23.4% (80) was 40% (32) male and 60% (48)female.

Airag is a Mongolian traditional fermented equine milkbeverage, also known as koumiss in some parts of the world, fermented by a co-culture of yeasts and lactic acid bacteria. Little information is available on the bacterial communities in Mongolian traditional airag made from raw mare’s milk. Lactobacillus spp., Lactococcus spp., Enterococcus spp., and Leuconostoc species were isolated from airag. Strains of enterococci, including E. faecium and E. faecalis, are known to produce bacteriocins. These are called enterocins and they generally belong to class II bacteriocins. However, detailed studies of bacteriocins from Enterococcus durans are rare. The aim of this study was to isolate and identify bacteriocin-producing lactic acid bacteria (LAB) issued from Mongolian airag (traditional fermented mare’s milk), and to purify and characterize bacteriocins produced by theseLAB.Identification of the bacteria (Enterococcus durans) wascarried out on the basis of its morphological, biochemical characteristics andcarbohydrate fermentation profile by API50CH kit and 16S rDNA analyses.The pH-neutral cell-free supernatant of this bacterium inhibited the growth of several Lactobacillus spp. and food-borne pathogens including Escherichia coli,Staphylococcus aureus and Listeria innocua. The antimicrobial agent (enterocin A5-11) was heat stable and was not sensitive to acid and alkaline conditions (pH 2–10), but was sensitive to several proteolytic enzymes. Its inhibitoryactivity was completely eliminated after treatment with proteinase K anda-chymotrypsin. Three-step purification procedure withhigh recovery yields was developed to separate two bacteriocins. The appliedprocedure allowed the recovery of 16% and 64% of enterocinsA5-11A andA5-11B, respectively, present in the culture supernatant with purity higher than99%. SDS-PAGE analyses revealed that enterocin A5-11 has a molecular massof 5000 Da and mass spectrometry analyses demonstrates molecular masses of5206 and 5218 Da for fractions A and B, respectively. Amino acid analyses ofboth enterocins indicated significant quantitative difference in their contents in threonine, alanine, isoleucine and leucine. Their N-termini were blocked hamperingstraightforward Edman degradation.The minimuminhibitory concentration of bacteriocinsA5-11A andA5-11B was8.2 µM l-1and 9,2 µM l-1, respectivelyBacteriocins A5-11A and B from Ent. durans belong to the classII of bacteriocins